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Quantitative genome re-sequencing defines
multiple mutations conferring chloroquine
resistance in rodent malaria
Katarzyna Kinga Modrzynska1,8, Alison Creasey1, Laurence Loewe2, Timothee Cezard3, Sofia Trindade Borges4,9,
Axel Martinelli5, Louise Rodrigues5,10, Pedro Cravo5,11, Mark Blaxter3,6, Richard Carter1 and Paul Hunt1,7*
Abstract
Background: Drug resistance in the malaria parasite Plasmodium falciparum severely compromises the treatment
and control of malaria. A knowledge of the critical mutations conferring resistance to particular drugs is important
in understanding modes of drug action and mechanisms of resistances. They are required to design better
therapies and limit drug resistance.
A mutation in the gene (pfcrt) encoding a membrane transporter has been identified as a principal determinant of
chloroquine resistance in P. falciparum, but we lack a full account of higher level chloroquine resistance. Furthermore,
the determinants of resistance in the other major human malaria parasite, P. vivax, are not known. To address these
questions, we investigated the genetic basis of chloroquine resistance in an isogenic lineage of rodent malaria parasite
P. chabaudi in which high level resistance to chloroquine has been progressively selected under laboratory conditions.
Results: Loci containing the critical genes were mapped by Linkage Group Selection, using a genetic cross between
the high-level chloroquine-resistant mutant and a genetically distinct sensitive strain. A novel high-resolution
quantitative whole-genome re-sequencing approach was used to reveal three regions of selection on chr11, chr03 and
chr02 that appear progressively at increasing drug doses on three chromosomes. Whole-genome sequencing of the
chloroquine-resistant parent identified just four point mutations in different genes on these chromosomes. Three
mutations are located at the foci of the selection valleys and are therefore predicted to confer different levels of
chloroquine resistance. The critical mutation conferring the first level of chloroquine resistance is found in aat1, a
putative aminoacid transporter.
Conclusions: Quantitative trait loci conferring selectable phenotypes, such as drug resistance, can be mapped directly
using progressive genome-wide linkage group selection. Quantitative genome-wide short-read genome resequencing
can be used to reveal these signatures of drug selection at high resolution. The identities of three genes (and mutations
within them) conferring different levels of chloroquine resistance generate insights regarding the genetic architecture
and mechanisms of resistance to chloroquine and other drugs. Importantly, their orthologues may now be evaluated
for critical or accessory roles in chloroquine resistance in human malarias P. vivax and P. falciparum.
Background
Despite advances in vector control and attempts to
develop effective vaccines, chemotherapy remains a prin-
cipal mode of malaria control. Unfortunately malaria
parasites resistant to drugs such as chloroquine (CQ)
have arisen by gene mutation; their prevalence increasing
by subsequent selection and transmission. These drug
resistant parasites seriously compromise efforts to treat
and control malarial disease both in individual cases and
in communities. The ability to describe, understand and
respond to these evolutionary processes continues to
depend upon the identification of the precise genetic
mutations which underlie the resistance phenotypes.
Also, an identification of the genes involved may lead to
insights regarding the mechanisms of drug action and
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resistance, and the design of improved drugs and treat-
ment strategies.
For chloroquine resistance (CQ-R), genetic linkage stu-
dies [1,2], other experimental approaches [3] and pheno-
type/genotype associations in parasites from natural
infections [3-5] have mapped and identified the K76T
mutation in the chloroquine resistance transporter,
pfCRT, as the dominant genetic determinant in the most
important human parasite Plasmodium falciparum. This
protein mediates the export of CQ from the parasite
digestive vacuole (DV) [6-8], its presumed site of action
[9]. Additionally, specific point mutations in the multi-
drug resistance gene (pfmdr1) encoding an ABC trans-
porter (P-glycoprotein homologue, Pgh-1) have also been
shown to modulate the level of resistance in CQ-R para-
sites in transfection experiments [10,11] and in associa-
tion studies using parasites from natural infections
[12,13]. However, these two genes neither account for
the full variation of in vitro CQ responses, including
high-level CQ-R (CQ-hiR) [4,14] nor the appearance of
CQ-R in another major human pathogen, P. vivax [15].
Understanding the genetic basis of CQ-R in the rodent
malaria parasite, P. chabaudi could illuminate both of
these questions; firstly, because, as in P. vivax, the ortholo-
gues of the pfcrt and pfmdr1 genes are not involved [16],
at least in an existing lineage (Figure 1A) of parasites
(strain AS); secondly because this same lineage contains
parasites (e.g. AS-sens, AS-3CQ and AS-30CQ) with dif-
ferent levels of CQ-R [17,18]. Previous classical linkage
analysis of a genetic cross between the CQ-R mutant AS-
3CQ and a genetically distinct sensitive strain, AJ, defined
a region of 250 kb on chromosome 11 (chr11) as that con-
taining the mutation conferring the first level of CQ-R
[19,20] but the critical gene or mutation was not identi-
fied. For P. chabaudi CQ-hiR in AS-30CQ, there has been
no previous quantitative description of higher level CQ-R
or CQ-hiR phenotypes, nor a systematic mapping of the
genetic loci containing the critical mutations. Indeed, even
the number of genes and mutations involved, and the sizes
of their effect have remained undefined [18].
For drug resistance in malaria, classical linkage analysis
of genetic crosses has proved effective in mapping single
genes conferring clear phenotypes [1-3,21]. Also, Quanti-
tative Trait Loci (QTL) approaches [22,23] or genome
wide association studies [24-26] have identified multiple
major loci contributing to drug-resistance phenotypes.
However, because these methods require the individual
characterisation of many parasite lines or clones, they
can be time-consuming or may fail to reveal the specific
identity of a critical gene. Accordingly, Linkage Group
Selection (LGS) [27] or QTL analysis were previously
combined with Illumina® whole genome re-sequencing
(WGS) to specify the mutations conferring resistance to
artemisinin (V2728F ubp1) [28,29], sulphadoxine (K392Q
mdr2) [30], or mefloquine and lumefantrine resistance
(mdr1 duplication) [31].
Here, we define the basic and high-level CQ-R pheno-
types, extend the LGS strategy to map the multiple loci
contributing to increasing levels of CQ-R, and use quanti-
tative WGS of >100,000 single nucleotide polymorphisms
(SNPs, differentiating the parental strains of the genetic
crosses) to improve their resolution. We propose that,
within these loci, mutations occur in the P. chabaudi AS-
lineage that confer CQ-R and CQ-hiR. We identify these
and additional mutations using WGS.
Results
The P. chabaudi AS lineage contains parasites with
increasing levels of CQ-R
In order to quantitate the CQ-R phenotypes in the AS
lineage, the clones AS-sens, AS-3CQ and AS-30CQ
[17,18] (Figure 1A) were passaged in mice treated with
either 0, 3 or 10 mg CQ kg-1 day-1. The growth of these
parasites (Figure 1B-D) demonstrated that there is an
increasing level of resistance to CQ within the lineage.
AS-sens parasites grew only in untreated animals. AS-
3CQ grew at 0 and 3 mg CQ kg-1 day-1 but not at 10 mg
CQ kg-1 day-1 while AS-30CQ was able to survive 10 mg
CQ kg-1 day-1. We therefore denoted the CQ responses
of these clones as CQ sensitive (CQ-S), CQ-R or CQ-hiR,
respectively. These data are consistent with a previous
proposal that multiple mutations confer CQ-hiR [18] in
this lineage, and suggest a suitable range of CQ doses for
dissecting the critical genetic loci in LGS experiments,
below. For example, we expected that parasites surviving
3 mg CQ kg-1 day-1 would be enriched with parasites
having CQ-R (and, possibly, CQ-hiR) phenotypes, while
those surviving 10 mg CQ kg-1 day-1 would be preferen-
tially enriched with CQ-hiR parasites only.
Improved LGS strategies resolve multiple large-effect
genes
In the case of drug resistance, LGS uses drug treatment
to select the uncloned progeny of a genetic cross
(between a drug-resistant clone and a genetically differ-
ent drug-sensitive parasite) before measuring the propor-
tions of parental alleles in the surviving parasites [32]. It
generates a genome-wide scan of selection, revealing
‘selection valleys’ that are regions of the genome where
the proportion of alleles from the drug-sensitive parent is
greatly reduced (in drug-treated parasites relative to
untreated parasites) and where the genes conferring
resistance are located.
In the present study, an uncloned backcross (AS-
30CQ × AJ) between the CQ-hiR clone AS-30CQ and
the genetically different CQ-S parasite, AJ was generated
and treated with different CQ doses (0, 1.5, 3, 10 or
20 CQ kg-1 day-1, day 0-2 post-inoculation) to map
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progressively the signatures of increasing CQ selection.
Firstly, the proportions of parental alleles in all popula-
tions were measured in the surviving parasites, using a
library of ~96 pyrosequencing assays [33] (LGS-pyro).
Secondly, we developed a novel approach to improve
the resolution and confidence of LGS mapping (see
Methods, Additional File 1 (section 1)), thus. We
defined an expanded set of genome-wide parental AS/AJ
SNPs by WGS of the sensitive parent AJ (Additional
File 2). 50-base paired-end reads (103-fold mean coverage)
were mapped against the 18.8 Mb Wellcome Trust Sanger
Institute (Hinxton, Cambridge, UK) AS reference
sequence (AS-WTSI). 92% of the reads mapped uniquely.
By filtering, we identified 104,667 high stringency SNPs in
AJ relative to AS-WTSI at a mean frequency of ~0.0056
substitutions/nucleotide, similar to previous estimates of
genetic diversity between the parental strains [34]. At
these SNP positions, by counting short sequencing reads
containing the AS or AJ base variant in populations of the
LGS parasites surviving 0 or 3 mg CQ kg-1 day-1 (88-fold
mean coverage for both), we quantitated the proportions
of AS and AJ alleles, and investigated (for each SNP) the
statistical significance of the difference between the allele
proportion after each of the two treatments.
The proportions of alleles (genome-wide) in the LGS
populations surviving 3 mg CQ kg-1 day-1, revealed by
LGS-Illumina and by LGS-pyro were remarkably similar
(Additional File 3) suggesting that the experimental
errors incurred by either methodology were small.
LGS-pyro revealed progressively distinct selection valleys
on chr11, chr03 and chr02 as the CQ dose increased
(Figure 2A). LGS-Illumina confirmed selection valleys on
chr11 (Figure 3A-D, Figure 4A) and chr03 (Figure 4A, B)
at 3 mg CQ kg-1 day-1. These data suggest that CQ-R phe-
notypes in the AS lineage are conferred by the action of a
major effect gene on chr11, confirming previous linkage
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Figure 1 P. chabaudi clones in the AS lineage and their chloroquine responses. A. The AS lineage of drug resistant mutants [35,55,56]. Each
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analysis [19,20], and for CQ-hiR, major effect genes on
chr03, and chr02.
Mutation in aminoacid transporter (A173E aat1) is
predicted to confer CQ-R
LGS-pyro identified a partial selection valley on chr11 at
1.5 mg CQ kg-1 day-1 which proved to be dominant at
3 mg CQ kg-1 day-1 (Figure 2A): For example, the propor-
tion of an AJ allele of marker pcpf06-1338 decreased from
69.2% in untreated infections to 2.5% under CQ selection.
Importantly, an independent genetic backcross between
the mefloquine- and CQ-resistant clone AS-15MF [35] (in
the same AS lineage, Figure 1A) and AJ also showed a
similar distinct selection valley on chr11 at 3 mg CQ kg-1
day-1 (Figure 2B). Both selection valleys coincided with the
250 kb region previously mapped by classical linkage ana-
lysis [20] (Figure 2B).
LGS-Illumina confirmed the selection valley (at 3 mg
CQ kg-1 day-1) on chr11 at high resolution and statistical
significance (Figure 3A-D). Here, a region at nucleotide
~1,000,000 where the proportion of AJ alleles reached a
minimum < 3%, was flanked on either side by regions of
increasing AJ-allele proportion. The gradual and regular
change in AJ allele proportion suggested the presence of
many independent recombinant clones in the cross pro-
geny. The differences in the gradients of the two slopes
forming the selection valley may reflect different local
recombination rates along the chromosome. These data
resolved the presence of a mutation that confers CQ-R,
close to nucleotide 1,000,000 on chr11. This locus corre-
sponds to the base of the selection valley as defined by
LGS-pyro (Figure 2A, B) and to the 250 kb locus pre-
viously mapped [20], confirming that the gene bearing the
mutation conferring CQ-R lies toward the right-hand end
of chr11.
WGS (Methods, Additional File 1 (section 1)) identified
a total of 7 point mutations (confirmed by dideoxyse-
quencing) in AS-30CQ relative to AS-sens (Table 1,
Table 2, Additional File 4), four of which are shared
between AS-30CQ and AS-15MF [29]. Of these four
mutations, only one maps to chr11; a non-synonymous
mutation (A173E) in a gene (PCHAS_112780) encoding
a predicted aminoacid transporter (aat1). It is found at
base 996,332 (Sanger Sept2009 assembly) coincident with
the floor of the chr11 selection valley (Figure 2B, 3B). We
concluded that the probability of failing to identify a gen-
uine point mutation (false negative) in this region is very
small, for three reasons. Firstly, > ~ 96 - 98% of the
AS-WTSI genome was covered by uniquely mapping
short-reads (36 - 41 bp) employed here [29] (theoretical
maximum ~ 98.5%). Secondly, the read coverage is high:
for 200 kb upstream and downstream of aat1 on chr11,
only 0.61% or 0.73% of bases showed a read coverage of <
5 or < 10, respectively (Additional File 5). Thirdly, we
identified a very low overall genome-wide substitution
frequency (7 point mutations/genome) in AS-30CQ
(Table 1, Table 2) relative to AS-sens.
Dideoxysequencing confirmed that the A173E aat1
mutation first appeared in the AS lineage in AS-3CQ,
along with the CQ-R phenotype (Table 1).
We therefore propose that aat1 A173E is the determi-
nant of CQ-R in this particular P. chabaudi lineage.
The A173E aat1 mutation shares some properties with
the determinant (K76T pfcrt) of CQ-R in P. falciparum.
For example, like pfcrt, aat1 is predicted to encode a 10-
transmembrane (TM) helix transporter (Figure 5A) and its
P. falciparum orthologue (PFF1430c) is targeted to the
membrane of the DV (D. Fidock, P. Moura, pers comm.).
The wild-type function of pfcrt is uncertain but amino
acid transport has been suggested [36,37]. Both K76T and
A173E mutations result in negative charge shifts. Residue
173 in aat1 is at the start of a highly conserved region
(Figure 5B) close to the start of the first TM-helix (TM1):
in pfCRT, residue 76 lies at the start of TM1, predicted to
be internal to the DV where CQ is thought to act. These
data suggest that AAT1 and CRT may share some struc-
ture/function relationships impacting on their physiologi-
cal function in the absence and/or presence of CQ.
Mutation in another transporter (T719N PCHAS_031370)
is predicted to confer intermediate CQ-R
LGS-pyro experiments showed that AS markers on
chr03 were selected at 3, 10 or 20 but not at 1.5 mg
CQ kg-1 day-1 (Figure 2A). On chr03, the proportion of
the AJ allele of marker pcpf02-0452 decreased from
79.3% (untreated) to 17.0% at 3 mg CQ kg-1 day-1.
LGS-Illumina analysis confirmed that AJ alleles are
reduced across the whole of chr03; from about 82% in
untreated parasites to about 16% in CQ-treated popula-
tion (Figure 4B). Details of the selection profile on
chr03 are consistent with a focus of selection close to
base ~480,000. The gradients of this selection valley are
not dissimilar to those observed on chr11 when observed
on a genome-wide scale (Figure 4A).
WGS of AS-30CQ revealed (Table 2) a non-synonymous
mutation (T719N, PCHAS_031370) at base 474,123 on
chr03, and dideoxysequencing confirmed that this muta-
tion arose between AS-3CQ and AS-30CQ (Table 1,).
However, this mutation does not appear in clones AS-
15MF and AS-ATN (Figure 1A, Additional File 6) - these
two clones being selected from AS-15CQ (non-clonal)
using mefloquine and artesunate, respectively. Instead,
AS-15MF and AS-ATN bear a 3 base deletion (I102del) in
the same gene (confirmed by dideoxysequencing). We
therefore suggest that both the T719N and I102del muta-
tions were partially selected by intermediate levels of CQ
in AS-15CQ prior to fixation during treatment with
CQ (AS-30CQ), mefloquine (AS-15MF) or artesunate
Kinga Modrzynska et al. BMC Genomics 2012, 13:106
http://www.biomedcentral.com/1471-2164/13/106
Page 4 of 16
ubp1
100
1
10
5 10 15 20 
PCHAS_031370
aat1
P. chabaudi chromosome
1 2 3 4 5 6 7 8 9 10 11 12 13 14
11.5 12 12.5 13 13.5 14
100
90
80
70
60
50
40
30
20
10
0
AS-15MF x AJ cross
AS-30CQ x AJ cross
%
 A
J
 a
ll
e
le
(approx) Genome position (Mb)
A
B
PCHAS_112780
aat1
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(AS-ATN) and subsequent cloning (Additional File 1, sec-
tion 3).
PCHAS_031370 is predicted to encode a 12 TM-helix
protein (Figure 5C) and its P. falciparum orthologue
PFB0675w is also predicted (but not yet experimentally
confirmed) to target the DV membrane (D. Fidock, P.
Moura, pers comm.). The T719N substitution occurs in a
large loop between TM11 and TM12, a highly conserved
region of the gene (Figure 5D). The I102del mutation is
predicted to locate to the centre of TM3 and to change
the overall prediction of TM domain structure (data not
shown). The general transmembrane domain structure
and DV localisation of PCHAS_031370 are therefore
similar to other proteins (pfcrt, pfmdr1, aat1) identified
as conferring or modulating CQ-R in P. falciparum or
P. chabaudi. These data suggest that the PCHAS_031370
T719N mutation confers an increased CQ-R phenotype.
Interestingly, the P. yoelii orthologue (PY05194) of
PCHAS_031370 lacks sequence corresponding to TM1
and TM2 that are otherwise present in other Plasmodium
spp. (Figure 5D). Wild-type P. yoelii (17X) had not been
exposed to antimalarial drugs but was reported to be highly
CQ-R [38]. We suggest the possibility that P. yoelii CQ-R
resistance might be related to this structural variation.
WGS of AS-30CQ also revealed a non-synonymous
mutation T707N in PCHAS_030200 at base 70,553 on
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Figure 3 LGS-Illumina reveals selection by chloroquine on chr11. Allele proportions (sensitive strain, AJ) in uncloned progeny of genetic
crosses using high-stringency quantitative AS/AJ SNPs. The position of aat1 point mutation is indicated at bottom of each panel, x. A. In the
absence of CQ, each dark blue cross denotes AJ SNP frequency at each AS/AJ SNP. The upper and lower binomial 95% confidence intervals for this
proportion are given in cyan and red, respectively. The black line averages the focal SNP with 50 SNPs on each side (95% confidence interval (CI) =
red, blue line). The frequent small changes of mean allele frequencies on a local scale are more likely to reflect stochastic effects rather than ‘real’
effects of selection. B. As “A“ but after growth in the presence of 3 mg CQ kg-1 day-1. C As “B“ without CI of individual SNPs. Colour coding denotes
probability that the observed allele frequency in the selected sample is significantly different from that in the unselected sample in “A"; red P < 10-
12, yellow P < 10-10, cyan P < 10-8, blue P < 10-6, and grey represents other points. D As C, but with 25% AF-reduction (statistics performed with AJ
frequencies (unselected population in “A“) are reduced by 25%, see Methods). For A - D, corresponding high-resolution pdf files enable detailed
inspection of individual SNPs, sliding-window means and standard errors, available from corresponding author on request.
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chr03 (Table 1, Table 2), predicted to encode a member
of the P. chabaudi-specific variant gene family (chabaudi
interspersed repeat, cir) [39]. This mutation maps to the
left-hand of chr03. The detailed LGS-Illumina profile of
AJ allele proportion (Figure 4B) supports the possibility
that this mutation too may contribute to an augmented
(intermediate) CQ-R. Dideoxysequencing confirmed that
this mutation is specific to AS-30CQ and does not appear
in either AS-15MF or AS-ATN.
Mutation in de-ubiquitinating enzyme (V2728F Ubp1) is
predicted to confer the highest level CQ-R
LGS-pyro shows that AS markers on chr02 are selected
at 10 and 20, but not at 0, 1.5 or 3 mg CQ kg-1 day-1
(Figure 2A): e.g. at 10 mg CQ kg-1 day-1 on chr02, the
percentage of AJ alleles of marker pcpf01-0158
decreased from 89.8% (untreated) to 14.0%. Further
resolution within the chromosome was not possible
because parasites surviving 10 or 20 mg CQ kg-1 day-1
were not analysed by LGS-Illumina. WGS had pre-
viously identified a single mutation (V2728F ubp1, for-
merly V770F [28]) on chr02 [29] in both AS-30CQ and
AS-15MF. It is the only mutation detected on chr02 and
occurred between AS-3CQ and AS-15CQ (during CQ
selection, Additional File 1 section 2). We conclude
therefore that ubp1 V2728F confers CQ-hiR. This muta-
tion was predicted to reduce the activity of a de-ubiqui-
tinating enzyme [28] and also to confer artemisinin
resistance in AS-30CQ, without previous exposure to
this drug [29]. It is therefore predicted to affect the
responses of malaria parasites to multiple drugs with
diverse chemical structures and modes of action.
Dideoxysequencing confirms that this mutation
appears in AS-30CQ and AS-15MF but not in AS-ATN.
Instead an alternative mutation V2697F (formerly,
V739F) ubp1 appears in AS-ATN [28]. As with the
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Figure 4 LGS-Illumina - genome-wide scans of chloroquine selection. Datapoint colours encoded as in Figure 3D; A whole genome, B
chr03, C chr10, D chr06. Point mutations and indels are indicated by x or filled circles, respectively, at the base of scans, as determined by
independent WGS of AS strains AS-sens, AS-30CQ. Corresponding high-resolution pdf files enable detailed inspection of individual SNPs, sliding-
window means and standard errors, available from corresponding author on request.
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Table 1 Phenotype and Genotype of Selected Clones of the AS P.chabaudi Lineage
gene abbreviation, chromosome, residue
dhfr1 aat11 0313702 cir1 ubp11 1015502
chr07 chr11 chr03 chr03 chr02 chr10 chr14 chr07 chr05
106 173 102 719 707 2728 162 intergenic intergenic
Clone or Strain PYR response CQ response
AJ Sensitive S Sensitive A I T T V Y wt wt wt
AS-sens Sensitive S Sensitive A I T T V Y wt wt wt
AS-PYR Resistant N Sensitive A I T T V Y mut 34 bp deletion wt
AS-3CQ Resistant N Resistant E I T T V Y mut 34 bp deletion > 1 kbp deletion
AS-15CQ this line is uncloned3
3
AS30CQ Resistant N Hi-Resistant E I N N F H mut 34 bp deletion > 1 kbp deletion
AS-15MF4 Resistant N Resistant E del4 T T F Y mut 34 bp deletion > 1 kbp deletion
The pyrimethamine (PYR) and CQ responses of clones of the AS lineage are shown along with all mutations detected in AS-30CQ (and other clones) relative to AS-sens. 1 dhfr, dihydrofolate reductase; aat, aminoacid
transporter; cir, chabaudi interspersed repeat; ubp, ubiquitin specific protease (de-ubiquitinating enzyme). 2 Refers to genes PCHAS_031370 or PCHAS_101550. 3 mixed genotype and phenotype, see Additional File 1.
4 Note that AS-15MF carries an alternative allele of PCHAS_031370, namely I102del. Single-letter amino acid code used: A, alanine; E, glutamate; F, phenylalanine; H, histidine; I, isoleucine; N, asparagine; S, serine; T,
threonine; V, valine; Y, tyrosine; del, codon deleted.
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alternative mutations in PCHAS_011370, we suggest that
these two alternative ubp1 mutations are partially selected
(by CQ treatment) in the uncloned parasite AS-15CQ.
Their differential selection and fixation in clones AS-
30CQ, AS-15MF and AS-ATN derived from AS-15CQ
after selection by CQ, mefloquine or artesunate are fully
discussed along with a complete resolution of apparent
contradictions regarding their linkage (or otherwise) with
alternative mutations in PCHAS_031370 (Additional
File 1, section 3).
Other mutations in AS-30CQ
Nine mutations are identified in AS-30CQ relative to AS-
sens; seven point mutations and two deletions (Table 1,
Table 2).
Four point mutations (on chr11, chr03 (two) and chr02)
are associated with signatures of CQ selection and were
discussed above. They all first appeared in the P. chabaudi
AS lineage (Figure 1A) in AS-3CQ or AS-30CQ (i.e.
during CQ selection).
A fifth point mutation was identified in AS-30CQ, as
predicted, on chr07. This mutation, S106N dhfr (encoding
dihydrofolate reductase) was confirmed by dideoxysequen-
cing to have first appeared in AS-PYR1. It was previously
shown to confer resistance to pyrimethamine [30,32,40].
Four mutations (two point mutations and two deletions),
identified in AS-30CQ, were not associated with signatures
of drug-selection. Three were confirmed by dideoxyse-
quencing; a non-coding point mutation on chr14, a 34 bp
non-coding deletion on chr07 (Additional File 7) (both first
appearing in AS-PYR1) and a non-synonymous point
mutation on chr10, namely Y162H PCHAS_101550 (ortho-
logue of P. falciparum PF14_0279) arising first in AS-
30CQ (i.e. during CQ selection). A fourth mutation could
not be confirmed by dideoxysequencing: extensive low or
zero-coverage and/or a small cluster of poor quality SNP
calls in AS-30CQ, (also in AS-15MF [29] but not in AS-
50S/P [30] strongly suggested a ~1 kb deletion on chr05
occurring first in AS-3CQ or AS-15CQ (i.e. during CQ
selection, Figure 1A). Other studies will be required to
evaluate whether these 2 point mutations and 2 deletions
are consistently neutral (and consequently randomly fixed
during cloning), or whether they play a minor role in drug
(pyrimethamine or CQ) resistance. Such roles could
include a weak selective advantage in the presence of drugs
or compensation for fitness costs incurred by the ‘drug
resistance’ mutations (for example, in the absence of drugs
or during transmission of parasites through mosquitoes).
The low probability of failing to identify point muta-
tions (false negatives) on chr11 was discussed in the
AAT1 section above. Similar arguments and data may be
applied equally to the whole genome (Additional File 5)
and are addressed more fully here (Additional File 1) and
previously [29]. Our conclusion is that the probability of
a false negative point mutation in central regions of a
chromosome is low (< 0.05). For regions of chromosomes
closer to the telomeres where P. chabaudi-specific genes
are located, we suggest that the probability of a false
negative is higher but not easily quantified. However,
with the exception of possible selection at the left hand
end of chr06, our experiments show no evidence of CQ
selection in these regions.
Genome-wide scan of selection - other observations
Both LGS-pyro and LGS-Illumina data indicated that AJ
allele proportions were high (~90%) in the untreated
LGS population but were reduced after drug treatment
(Figure 2A, 4A) at many loci genome-wide, including
chromosomes other than chr02, chr03 or chr11. For
example across chr10 (Figure 4C) AJ allele proportions
Table 2 Illumina® whole-genome re-sequencing - Confirmed and High-Confidence Mutations in AS-30CQ
Chr Nucleotide number WTSI AS-
30CQ
Quality
Score
Mutation Gene
(abbrev)
Nearest Gene P. falciparum
orthologue
POINT MUTATIONS
2 216,954 C A 99 V2728F PCHAS_020720 PFA0220w
3 70,553 G T 99 T707N PCHAS_030200 none
3 474,123 C A 99 T719 PCHAS_031370 PFB0675w
7 994,546 G A 99 S106N PCHAS_072830 PFD0830w
10 634,932 T C 99 Y162H PCHAS_101550 PF14_0279
11 996,332 G T 99 A173E PCHAS_112780 PFF1430c
14 936,945 T G 92 PCHAS_142600 PF08_0081
DELETIONS
Start (nucleotide
number)
Finish (nucleotide
number)
5 683,724 684,989 PCHAS_051920 none
7 876,909 876,914 PCHAS_072420 PF08_0067
Summary of the high confidence mutations proposed in clone AS-30CQ (see Additional File 1). Read depth and quality scores fro mutations were according to
SSAHA2. Start and Finish nucleotides for deletions are approximate only.
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were reduced from ~86% to ~65%, after drug treatment
(3 mg CQ kg-1 day-1). These data may reflect high AJ
proportions in the backcross and the loss of AJ parental
parasites (present in a significant proportion) after CQ
treatment. Additionally, or alternatively, AJ alleles may
have been positively selected during growth without
drugs, reflecting the possible action of multiple (small
effect) genes that underlie the faster growth of AJ com-
pared to AS parasites, observed routinely in previous
experiments [41,42].
The LGS-pyro data showed that the selection valleys on
chr11, 03 and 02 were produced progressively at increas-
ing CQ doses (Figure 2A). Thus, low doses resulted in
the selection of AS alleles on chr11, and increasing doses
resulted in selection of AS alleles on chr03 and then on
chr02. We note that the maximum depth of the chr11
selection valley was reached at a lower CQ dose than that
required to achieve maximum selection at chr03 (and
additionally for chr02). These data may be interpreted by
invoking two possible factors. Firstly, we suggest that the
mutations conferring CQ-hiR on chr03 and on chr02
may incur ‘fitness costs’: i. e. that in the absence of a suf-
ficiently high concentration of CQ, these mutations may
reduce the growth of parasites. This would mean that, at
lower CQ concentrations, parasites with CQ-R (bearing
only the 173E aat1 allele) would be selected to a greater
degree than CQ-hiR parasites bearing multiple muta-
tions. Secondly, the effects of the mutations on chr03
and/or chr02 may be epistatic to the A173E aat1 muta-
tion, because mutated AS alleles at these loci (chr03 and
chr02) only show signs of selection (at higher doses of
CQ) after the selection of mutated AS alleles at the aat1
locus (chr11) (at lower doses of CQ). According to this
interpretation, parasites bearing only the mutations on
A173E
A C
B D
T719N
I102del
P.falciparum    140 SDGD-YTNDEEGTNKPKRNWKGRTFSRFTPGGVRSSTVLFICTAIGVGFL 188 
P.vivax         164 GENEKNPEDEEAEKS-KKNWQRRTFSRFTPGGVRSSTVLFICTAIGVGFL 212 
P.knowlesi      190 GGNEKNAQDKEEEKKRKKNWKRRTFSRFTPGGVRSSTVLFICTAIGVGFL 239 
P.chabaudi      150 NENGKNKLCEENETNTKKTWQKRAFGPFTPGGVRSSTVLFLCTAIGVGLL 199 
P.berghei       147 NEKGKNKLYEENQTNTKKTWKRRAFSPFTPGGVRSSTVLFLCTAIGVGLL 196 
P.yoelii        159 NEKEKNKIYEENQTNKKKTWKKRTFSPFTPGGVRSSTVLFLCTAIGVGLL 208 
                    .        :*  .. *:.*: *:*. *************:*******:* 
P.falciparum    91 YFNMAMLLFFSIIIPFLKLLMVSDNFYSFIVLYKMNKKREEEKRRRR 137 
P.vivax         91 YFNMAMLLLFSIIIPILKLIMVSDNFYCFFKLYNLSLQHEEEEKEEE 137 
P.knowlesi      90 YFNMGMLLFFSIIIPILKFIMVSDNFYCFFKLYNLSLQHEEEEKEEE 136 
P.chabaudi      90 YFNMGVLLIFSVIIPILKFVMVTDNFYSFFKLYNLGLKFNENDKDD- 135 
P.berghei       90 YFNMGVLLIFSVIIPVLKFVMVSDNFYSFFKLYNLSLNFNENDKDD- 135 
P.yoelii         1 ---MGVLLIFSVIIPVLKFIMVSDNFYSFFKLYNLSLNINENDKDD- 43 
                      *.:**:**:***.**::**:****.*: **::. : :*:.:    
 
 
 
P.falciparum   826 KFSEIVDLNTQKGDGDHFDETQIFSIFFSFLIKKNE--GSKMRDNDMNSD 873 
P.vivax        777 RYSEIVDLNIQK---HEHWHVPIYSYFFQFLLKKEHFFSSSLKHNHITK- 822 
P.knowlesi     777 RYSEIVDLNIQK---HEHWHVPIYSYFFQFLLKKEHFFSPSIKHNQITK- 822 
P.chabaudi     698 RCSEIVDLNIQK---NKNWTIPIYTYFFKSLIKPNQIVFKKNKKIDISE- 743 
P.berghei      694 RCSEIVDLNIQK---NKNWNIPIYTYFFKFLIKQNQNILKKKKKIDISQN 740 
P.yoelii       595 RCSEIVDLNIQK---NKNWNIPIYTYFFKFLIKQNQNIFKKKNKINISQD 641 
                      : ******* **   ..     *:: **. *:* :.    . .. .:..  
Figure 5 Structure and sequence conservation of P. chabaudi AAT1 and PCHAS_031370 and their orthologues. Secondary structure
predictions of AAT1 (A) and PCHAS_031370 (C) proteins reveal 10 and 12 TM-helix proteins, respectively. The mutations discovered within CQ-R
and CQ-hiR P. chabaudi parasites (AS-3CQ and AS-30CQ, respectively) are highlighted (magenta). The alignments of Plasmodium spp. protein
fragments (B, D) indicate the positions of mutations in, or close to, conserved regions.
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chr03 or chr02 (or both) are not selectable by lower
doses of CQ.
The LGS-Illumina analysis revealed an abrupt disconti-
nuity of AJ proportion at the right hand end of chr11
(Figure 3A-D) and similar changes on chr05, 07, 09, 12,
13 and 14 (Figure 4A, Additional File 8), often in both
untreated and drug-treated parasites. These are described
and discussed in Additional File 1, section 4. These dis-
continuities are also observable in the LGS-pyro data.
Our conclusion is therefore that they are not artefacts of
LGS- Illumina. Also, they did not arise by natural genetic
or selection phenomena. They are most likely to arise
from differences (in genome assembly) between AS-
WTSI (reference strain) and our parental strains AS-sens
and/or AJ.
LGS-pyro and LGS-Illumina revealed regions showing
possible weak drug selection but where mutations were
not detected; for example, the left-hand end of chr06
(Figure 4D). Further studies are required to investigate
whether these represent reproducible regions of selection
or arise from random variation.
Discussion
We have described in vivo CQ-R and CQ-hiR phenotypes
in the genetically related P. chabaudi AS parasites AS-
3CQ and AS-30CQ, mapped the underlying genetic loci
on chr11 (CQ-R), chr03 and chr02 (CQ-hiR) and, by
WGS, have identified a small number of mutations pro-
posed to confer these phenotypes. A173E aat1 (on chr11)
is proposed to confer CQ-R. T719N PCHAS_031370
(transporter on chr03) and V2728F ubp1 (on chr02) are
proposed to confer CQ-hiR. We also suggest that T707N
PCHAS_030200 (cir gene on chr03) may also contribute
to CQ-hiR.
Mutations conferring CQ-R are identified by integrating
genetic and genomic data
The genetic (LGS-pyro and LGS-Illumina) and genomic
(WGS) approaches employed showed a remarkable con-
cordance on chr02, chr03 and chr11: i.e. these major selec-
tion valleys contain 4 of the 6 mutations that arose in the
lineage under CQ selection (from AS-PYR1 to AS-30CQ).
The genome-wide scans do not reveal selection around
the other two mutations arising during CQ selection
(Y162H PCHAS_101550, chr10; > 1 kb deletion, chr05)
nor around those (three) arising during previous pyri-
methamine selection (in AS-PYR1, Figure 1A); i.e. 34 bp
deletion and S106N dhfr) (both chr07), non-coding point
mutation (chr14).
The correspondences between the genetic and genomic
data and the arguments deployed previously [29] and
above (Results - other mutations in AS-30CQ) together
suggest that only 3-4 major effect genes conferring CQ-R
and CQ-hiR were fixed by strong selection (and cloning)
during experimental evolution from AS-sens to AS-30CQ.
Furthermore, only a small number of weakly selected or
effectively neutral mutations were fixed stochastically dur-
ing population bottlenecks such as those occurring during
transmission of parasite lines, or experimental cloning.
Previous similar investigations in the P. chabaudi AS
lineage demonstrated that one mutation conferred resis-
tance to each of pyrimethamine, sulphadoxine [30], meflo-
quine [31] and artemisinin [29] and that ≤ 3 mutations
were fixed stochastically each time during the selection
and cloning of AS-50S/P, AS-15MF and AS-30CQ respec-
tively. The low rate of nucleotide substitution, even during
multiple passages and bottlenecks, makes this system well
adapted for investigations of resistance to other drugs.
The genetic architecture of CQ-R
CQ-hiR was previously generated in AS-30CQ of the
P. chabaudi AS-lineage by drug selection over about 40
passages [17,18], leading to the suggestion that the CQ-
hiR phenotype arose by a series of small steps and was
mediated by several mutations at different loci, although
the number of mutations was not predicted. Actually,
for CQ-R, the present data strongly support the contri-
bution of aat1 (chr11) as a single major effect gene,
confirming previous classical genetic linkage analysis
[19,20]. For CQ-hiR, two (or three) major effect genes
(PCHAS_031370 (transporter) and ubp1, on chr03 and
chr02, respectively) are strongly supported. In this
respect, the architecture of CQ-R in P. chabaudi may be
similar to that of P. falciparum where pfcrt and pfmdr1
alleles appear to generate high levels of CQ resistance
epistatically [12,13]. The hypothesis that CQ-hiR in
P. chabaudi is mediated by a large number of small-
effect mutations is rejected by the data presented here.
The genetic determinants of CQ-R
The concordance between the phenotypic, genetic and
genomic data strongly supports the identification of muta-
tions in AAT1 as the key determinant of CQ-R. We have
also revealed shared properties of pfcrt and aat1 and their
mutations (K76T, A173E, respectively), such as putative
function (amino acid transport), subcellular location, TM-
helix topology, type and position of mutation. Genome-
wide transcription profiling of the CQ-S P. falciparum
parasite (strain 106/1) and CQ-R transfectants identified
the aat1 orthologue PFF1430 as one of a small number of
differentially expressed genes [37] which also included
genes predicted to encode transporters, proteases and
components of the trafficking pathways. This suggests
future transfection and functional studies to address ques-
tions regarding the role of these mutations in amino acid
or CQ transport and CQ-R in P. falciparum and P. cha-
baudi. The involvement of aat1, another (chr03 encoded)
DV transporter and ubp1 in CQ-hiR also provoke
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questions regarding the relationship between haemoglobin
digestion, protein turnover, amino acid transport/availabil-
ity and CQ action, export and resistance phenotypes.,
Interestingly, the V2728F ubp1 mutation has now been
shown to confer resistance to both artemisinin [29] and
chloroquine (this study). This resolves a previously unex-
plained result - that artemisinin resistance mediated by
mutations in ubp1 appeared before parasites were exposed
to artemisinin. This data also suggests that there must be
some commonality in the molecular mechanisms of resis-
tance to the two drugs, at least in the P. chabaudi AS
lineage.
The rodent model and public health
P. chabaudi and P. falciparum have similar or identical
genetic bases for resistance to pyrimethamine (point muta-
tions in dhfr, [30]) and to mefloquine (mdr1 amplification)
[31]. For CQ-R, both parasite species share key features
(e.g. reduced CQ accumulation in DV [43], changes in DV
morphology [44] and verapamil reversibility [45]). Now,
notwithstanding the evidence supporting the proposal that
different genes confer CQ-R in the two species, the data
presented here suggest that some features of the molecular
mechanism of resistance acquisition may be similar. This
supports the use of the rodent model to identify candidate
genetic markers of resistance to future antimalarial drugs.
Furthermore, the orthologues of aat1 (PVX_114575,
PFF1430c) and PCHAS_031370 (PVX_002795, PFB0675w)
should now be evaluated as candidate molecular markers
of CQ-R in P. vivax and modulators of CQ responses in
P. falciparum.
The experiments reported here share some features pre-
viously exploited by genome-wide selection scans in yeast
[46], genome-wide association [26] and high-resolution
identification of mutated genes [47,48] in P. falciparum.
The present study demonstrates how similar approaches
can be used to identify genes conferring complex select-
able phenotypes such as drug-resistance in experimental
systems.
Conclusions
Previously, increasing chloroquine resistance phenotypes
were experimentally selected in a lineage of the rodent
malaria, Plasmodium chabaudi. Here, these phenotypes
were measured, the underlying genetic loci mapped and
mutations specified using a novel quantitative genetics and
genomics approach.
This approach analysed genetic crosses by selecting pro-
geny en masse at different drug concentrations. The fre-
quencies of parental alleles in the surviving parasites were
measured using ~ 100 pyrosequencing single nucleotide
polymorphism (SNP) assays, and for ~100,000 single
nucleotide polymorphisms, by Illumina short-read sequen-
cing. This defined ‘selection valleys’ on chromosomes 11,
3 and 2, where genes conferring resistance were expected
to be located. Whole genome re-sequencing of the chloro-
quine resistant mutant parasite and the sensitive progeni-
tor wild-type parasite showed that only 7 point mutations
in the whole genome had arisen in the lineage. The speci-
fic isolated mutations within the selection valleys were
identified. A mutation in a putative aminoacid transporter
(aat1) encoded on chr11 confers chloroquine resistance.
Mutations in another transporter (PCHAS_031370, chr03)
and a deubiquitinating enzyme (ubp1, chr02) confer
higher level chloroquine resistance. Orthologues of these
genes in P. falciparum and P. vivax can now be studied
for their contribution to chloroquine resistance in human
infection. These data will generate insights of the mechan-
ism of chloroquine resistance in human and rodent
malaria parasites.
Methods
Parasite and mouse strains, routine passage
AJ and AS-sens are chloroquine (CQ) sensitive clones of
the rodent malaria Plasmodium chabaudi chabaudi, iso-
lated from wild-caught Thamnomys rutilans thicket rats
from the Central African Republic [49]. AS-PYR, AS-3CQ
and AS-30CQ were selected (and cloned) sequentially
from AS-sens by pyrimethamine, CQ and high CQ con-
centrations progressively and respectively [18,50]. All
resistant phenotypes were heritable and stable after clon-
ing, freeze/thaw cycles, passage of parasite without drug,
and after transmission through the mosquito host. Six- to
eight-week old laboratory CBA female mice were used for
all the experiments with the exception of mosquito trans-
mission when C57/BL6 mice were used. All animals were
housed and maintained according to the standard animal
husbandry conditions, with free access to food (RM3 diet)
and PABA supplemented water. All experiments were
conducted in compliance with the United Kingdom Ani-
mals (Scientific Procedures) Act 1986.
Drug phenotyping
Mouse infections were initiated with an intraperitoneal
inoculum of 106 parasites and treated with CQ sulphate
(Beacon Pharmaceuticals) diluted to appropriate concen-
tration with water and administered to a 20 g mouse by
gavage in 100 μl. The treatment was repeated for the first
3 days of infections (d0-2 post-infection (p.i.)). The parasi-
taemia of all infections was monitored by daily thin blood
smears as described previously [29]. Each treatment group
consisted of three animals.
AS-30CQ × AJ backcross and LGS
The AS-30CQ × AJ cross was performed by allowing
Anopheles stephensi mosquitoes to feed upon anaesthe-
tised C57/BL6 mice infected with mixture of both strains,
according to the protocol established previously [29].
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After 14-15 days, salivary glands were dissected and spor-
ozoites injected into donor mice. The recovered cross-
progeny asexual forms were further passaged, treated
with 0, 1.5 or 10 mg CQ kg-1 day-1 for three days, and
pooled in order to increase the numbers of resistant
recombinants in the mixture. The resulting parasites
were backcrossed with the sensitive parent (AJ) using the
same procedure as above. The backcross recombinant
progeny were selected en masse with 0, 1.5, 3, 10 and 20
mg CQ kg-1 day-1 (d0-2 p.i.) in groups of 5 mice each.
When parasitaemias within a group reached > 10%,
blood was harvested, pooled and DNA isolated using the
protocol previously described [34].
Pyrosequencing
The PSQ™ HS-96A pyrosequencing system was used to
measure the proportion of AJ alleles in all selected back-
cross populations. A set of ~96 uniformly spaced, quanti-
tative pyrosequencing assays measuring the proportion of
the SNPs between the AS and AJ were designed as pre-
viously described [33]. The pyrosequencing assays were
prepared and performed according to the manufacturer’s
instructions, each assay being performed in triplicate, on
three different template samples.
Genome re-sequencing and mutation detection in
AS-30CQ
The chloroquine resistant AS-30CQ genome and that of
its sensitive progenitor AS-sens were sequenced with
50 and 36 base single reads at approx 80- and 40-fold cov-
erage, respectively by the GenePool Genomics Facility
http://genepool.bio.ed.ac.uk/. The single end reads
obtained for AS-30CQ were aligned against the isogenic
P. chabaudi AS strain reference genome ftp://ftp.sanger.ac.
uk/pub/pathogens/P_chabaudi/Archive/September_2009_-
assembly/ using the MAQ [51]http://maq.sourceforge.net/
maq-manpage.shtml and SSAHA2 [52] ftp://ftp.sanger.ac.
uk/pub/zn1/ssaha_pileup/ssaha_pileup-readme software
suites. The SNPs and indels between the two strains were
identified and analysed (Additional File 1, section 1) as pre-
viously described [29].
Quantitative sequencing (LGS-Illumina)
AJ and the AS-30CQ × AJ backcross (surviving 0 or
3 mg CQ kg-1 day-1) were each sequenced using ~2 μg
of DNA on single lanes, using 50 base paired end reads
that were mapped against the AS-WTSI reference
sequence (PlasmoDB 6.3 version, 17 Feb 2010) using
BWA (v0.5.8) software [53]. For AJ/AS SNP detection,
unique reads with mapping quality > 30 and bases with
base quality (Phred-like code) > 20 were used. SNPs
were called in positions covered by at least 10 reads if at
least 30% of the bases are different from the reference.
SNP selection
113,746 candidate AS/AJ SNPs were determined by Illu-
mina® whole-genome re-sequencing (WGS) of CQ-sen-
sitive parental strain AJ (relative to reference strain
sequence AS-WTSI). Of these 838 (0.74%) are in contigs
that are currently not assembled in the 14 chromosomes
and were ignored in the analysis presented here. For
inclusion in the plots presented in this work, the
remaining 112,908 SNPs were further filtered using the
following criteria: (i) ≥ 20 reads in all samples (i.e. the
AJ sequence sample, the untreated cross-progeny
sequence sample and the CQ-treated cross-progeny
sequence sample, (ii) > 90% frequency of the AJ base-
call in the AJ sequence sample (usually this is 100%).
SNPs failing these criteria (7,079) were excluded leaving
104,667 SNPs for the genome wide scan of selection.
The numbers of AS and AJ nucleotide calls at these
SNPs were determined from the sequencing data of AJ
and AS-30CQ × AJ (untreated and treated at 3 mg CQ
kg-1 day-1) samples using custom scripts.
Statistics - Binomial test
The quantitative LGS-Illumina analysis samples reads
from a population of individual clones that are the
result of the recombination and selection processes
described above. For each SNP the finite sampling size
results in random deviations from the expected value
for the true allele proportion. These random deviations
can be described by the binomial distribution, which is
the basis of the tests for statistical significance we
employ. As expectation p we use the point estimate
obtained from our data, where the ‘number of suc-
cesses’ x are given by the number of AJ alleles
observed and the total number of attempts n is given
by the sum of AJ + AS alleles sequenced (usually equal
to the number of reads containing the SNP). We use a
two-sided binomial test with a confidence limit of 95%
throughout the paper. This means that strong AF-
reductions (see below) can result in “significant” points
at high AJ allele frequencies, indicating possible selec-
tion for AJ alleles.
Statistics - sliding window analysis
Because the frequencies of individual SNPs come with
binomial variability, we sought to estimate the local AJ
proportions with reduced sampling error by combining
neighbouring SNPs in a sliding window analysis (on the
assumption that the real AJ allele frequency was constant
over this scale). We summed x and n for 101 neighbour-
ing SNPs (50 on each side of a focal site) and computed
upper and lower limits (using binomial test described
above), shown by blue and red lines in Figure 3A-D and
Figure 4A-D.
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Statistics - AF-reduction
As described in ‘Results’ and elsewhere [29], there are fac-
tors that may reduce AJ allele proportions at loci not
linked to the drug resistant phenotype in drug-treated
samples relative to untreated samples. The effects of these
factors are very difficult to estimate precisely. We there-
fore increased the stringency of our statistical analysis by
applying a correction parameter, termed “Allele Frequency
Reduction” (AF-reduction). This parameter reduces the
observed % of AJ alleles in the untreated population (in
order to correct for additional and confounding factors,
such as the removal of AJ parental parasites). To test the
robustness of our conclusions we tested the significance of
differences between the drug-treated and the untreated
samples with AF-reduction = 0% and 25%. We then com-
puted the probability that our drug-treated samples could
have been produced by allele frequencies as observed in
the point estimates of our untreated samples. These prob-
abilities are indicated by the colour of each SNP shown
(Figure 3C, D and Figure 4A-D). In these plots, we high-
light probability P < 10-6 as an important threshold by
coloured data points. The choice of this threshold can be
justified by considering the large number of SNPs used in
this test (approximate Bonferroni correction). At AF-
reduction = 25% we found 7342 SNPs that deviated from
their expected values with P < 10-12 (red in Figure 3C, D,
4A-D), 3588 with 10-12 < P < 10-10 (yellow), 5945 with 10-
10 < P < 10-8 (cyan) and 9272 with 10-8 < P 10-6 (blue). In
these SNPs, the AJ-allele proportion was either below or
above the expected values with the specified probability.
Lower SNP frequencies indicate the valleys of selection
caused by resistance mutations. Higher SNP frequencies
could indicate the presence of AJ alleles benefiting the
growth of parasites in the presence of drugs and other
more complex growth, virulence and immunity traits.
Alternatively, many significant higher SNP proportions
might indicate that the AF-reduction operation was too
large.
The confirmation of predicted mutations
The presence of all mutations predicted between the AS-
sens and AS-30CQ clones was confirmed using standard
PCR and dideoxysequencing using primers presented in
Additional File 9. Additional clones from the AS lineage
(AS-PYR, AS-3CQ, AS-15MF, AS-ART and AS-ATN)
were also tested, when required, to determine and confirm
when mutations arose in the lineage.
Proportional sequencing
The proportions of mutant alleles at aat1, PCHAS_031370
and ubp1 genes were measured in untreated and treated
populations of parasites using proportional sequencing as
described previously [54]. The fragments containing the
pre-defined mutations were amplified and sequenced
using specific primers (Additional File 9). The resulting
electropherograms were analyzed using Chromas 2.33
software (Technelysium Pty Ltd) and the heights of peaks
corresponding to the wild-type and mutated nucleotides
measured. These were used to calculate an index of the
respective proportion of the wild-type allele (AJ) in the
population.
Homology studies and protein structure predictions
The orthologues of mutated genes were identified in
other Plasmodium spp. using PlasmoDB database and
the alignments produced using ClustalW2 software
http://www.ebi.ac.uk/clustalw/. The positions of TM-
helices in both proteins was predicted using TMpred
software http://bioinformatics.biol.uoa.gr/TMRPres2D/
and visualised using TMRPres2D java applet http://liao.
cis.udel.edu/website/servers/TMMOD/.
Additional material
Additional file 1: Additional Text. Section 1, Solexa genome re-
sequencing; Section 2, Other mutations in AS-30CQ; Section 3, AS-15CQ
and the origins of different haplotypes in subsequent clones; Section 4,
Discontinuities in AJ allele frequency.
Additional file 2: (Table) Solexa whole-genome re-sequencing
metrics.
Additional file 3: (Figure) LGS-pyro v LGS-Illumina. Comparison of
genome scans (LGS-pyro (top), LGS-Illumina (bottom)) show near perfect
correspondence between the two methodologies. Vertical axis (linear)
indicates proportion of AJ alleles in parasites surviving 3 mg CQ kg-1 day-
1. Horizontal axis indicates chromosome number, top and bottom or
genome co-ordinate (Kbase), top only. Position of mutations (AS-30CQ
relative to AS-sens) are indicated at bottom of bottom panel (7 SNPs x, 2
deletions •).
Additional file 4: (Table) AS-30CQ Genome re-sequencing. Summary
of all the mutations proposed in clone AS-30CQ (Additional File 1).
Highlighted are mutations confirmed by di-deoxy sequencing (green),
rejected mutations (red), a high confidence deletion (yellow) and low
confidence mutations (orange). Read depth according to SSAHA2 is
provided for SNPs. All quality scores for SNPs were according to SSAHA2.
Small indel quality scores indicate the number of reads calling an indel
divided by the total number of reads covering the indel. For large indels
and CNVs, a comparative coverage was calculated as described (Methods
section and Additional File 1).
Additional file 5: (Table) Genome-wide analysis of % of bases with
read-coverage ≥ 10.
Additional file 6: (Figure) The appearance of mutations in the AS
lineage. Mutations are described by chromosomal location, gene ID,
specific amino acid change etc. Some were previously described [29,30]
(blue). Novel mutations are identified here (red). For both PCHAS_030137
and ubp1, alternative mutations arising between AS-3CQ and AS-15CQ
(and individually selected in AS-15MF [31,35] and AS-ATN [55] during
mefloquine and artesunate selection, respectively) are defined (a-d). Refer
to Additional File 1(section 3) for further details.
Additional file 7: (Figure) Chromosome 7 - 34 bp deletion. Close to
the 3’ end of gene PCHAS_072420, an alignment of nucleotide
sequences for reference genome sequence (AS-WTSI), the sensitive AS
lineage progenitor (AS-sens) and the drug resistant mutants AS-PYR, AS-
3CQ, AS-30CQ and AS-ART is shown. Symbols: -,34 bp deletion in AS-PYR
and subsequent clones (wrt nt 197 - 230 (AS-WTSI arbitrary numbering)
inclusive), 15 bp deletion in AS strains (wrt nt 306 - 320 (AJ arbitrary
numbering) inclusive); *, nucleotides identical in all clones and strains
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investigated here (note high frequency of AS/AJ SNPs). 3’ end of coding
sequence of gene PCHAS_072420 is indicated (upper case, green
highlighting); intron (lower case, grey highlighting), 3’-UT and intergenic
region indicated (lower case); termination codon (red). Repetitive
sequences which may mediate the 34 bp and 15 bp deletions are
indicated (yellow) in individual representative clones.
Additional file 8: (Table) Discontinuity co-ordinates. Co-ordinates
represent nucleotide position on chromosome relative to the AS-WTXI
sequence assembly (Sanger Sept 2009); nd, cannot be determined.
Additional file 9: (Table) Primers used. These oligonucleotide primers
were used to confirm the predicted mutations in AS lineage. Pairs of
primers marked with * were also used for proportional sequencing.
Abbreviations
AAT1: amino acid transporter 1; ABC: ATP-binding cassette; CQ: chloroquine;
CQ-R: chloroquine resistant: chloroquine resistance; CQ-hiR: high level
chloroquine resistance; CRT: chloroquine resistance transporter; DV: digestive
vacuole; LGS: linkage group selection; LGS-pyro: LGS analysed by
pyrosequencing; LGS-Illumina: LGS analysed by quantitative Illumina whole-
genome sequencing; Pgh-1: P-glycoprotein homologue-1; QTL: quantitative
trait loci; SNP: single nucleotide polymorphism; TM: transmembrane; WGS:
whole genome (re-)sequencing; WTSI: Wellcome Trust Sanger Institute.
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